Delcath Systems (OTCMKTS:DCTH) and SANUWAVE Health (OTCMKTS:SNWV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Analyst Recommendations

This is a summary of recent ratings for Delcath Systems and SANUWAVE Health, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems 0 0 2 0 3.00
SANUWAVE Health 0 0 0 0 N/A

Delcath Systems currently has a consensus target price of $19.50, indicating a potential upside of 109.45%. Given Delcath Systems’ higher possible upside, research analysts clearly believe Delcath Systems is more favorable than SANUWAVE Health.

Risk & Volatility

Delcath Systems has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, SANUWAVE Health has a beta of -0.73, meaning that its share price is 173% less volatile than the S&P 500.

Valuation and Earnings

This table compares Delcath Systems and SANUWAVE Health’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Delcath Systems $1.58 million 16.26 -$8.88 million N/A N/A
SANUWAVE Health $1.03 million 76.58 -$10.43 million N/A N/A

Delcath Systems has higher revenue and earnings than SANUWAVE Health.

Institutional & Insider Ownership

0.4% of SANUWAVE Health shares are held by institutional investors. 4.2% of Delcath Systems shares are held by company insiders. Comparatively, 23.4% of SANUWAVE Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.


This table compares Delcath Systems and SANUWAVE Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Delcath Systems -561.96% N/A -79.09%
SANUWAVE Health -1,122.95% N/A -465.37%


Delcath Systems beats SANUWAVE Health on 7 of the 10 factors compared between the two stocks.

Delcath Systems Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

SANUWAVE Health Company Profile

SANUWAVE Health, Inc., a shock wave technology company, focuses on the development and commercialization of noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications worldwide. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead product candidate is the dermaPACE device, which has completed its initial Phase III, IDE clinical trial for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. It markets and sells its devices and accessories. SANUWAVE Health, Inc. was founded in 2005 and is headquartered in Suwanee, Georgia.

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with's FREE daily email newsletter.